Epcoritamab + Rituximab and Lenalidomide vs. Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma

Disease Types: Lymphoma

Available at: Roanoke

A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma 

For More Information:

https://clinicaltrials.gov/study/NCT06191744?term=Epcoritamab%20%2B%20Rituximab%20and%20Lenalidomide%20(R2)&rank=4